4//SEC Filing
Parrish Jay 4
Accession 0001209191-21-025194
CIK 0001706431other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 5:00 PM ET
Size
12.7 KB
Accession
0001209191-21-025194
Insider Transaction Report
Form 4
Parrish Jay
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2021-04-01$1.49/sh+4,629$6,874→ 13,889 total - Sale
Common Stock
2021-04-01$51.40/sh−6,944$356,956→ 9,260 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-01−2,315→ 37,037 totalExercise: $1.57Exp: 2028-07-19→ Common Stock (2,315 underlying) - Exercise/Conversion
Common Stock
2021-04-01$1.57/sh+2,315$3,646→ 16,204 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-01−4,629→ 4,630 totalExercise: $1.49Exp: 2027-10-05→ Common Stock (4,629 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.
- [F2]1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F3]1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Vir Biotechnology, Inc.
CIK 0001706431
Entity typeother
Related Parties
1- filerCIK 0001786372
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 5:00 PM ET
- Size
- 12.7 KB